The p53 reactivator PRIMA-1MET synergises with 5-fluorouracil to induce apoptosis in pancreatic cancer cells
- PMID: 37402008
- DOI: 10.1007/s10637-023-01380-5
The p53 reactivator PRIMA-1MET synergises with 5-fluorouracil to induce apoptosis in pancreatic cancer cells
Abstract
Pancreatic cancer (PC) is one of the deadliest malignancies; p53 is mutated in approximately 75% of PC patients. Hence, the protein derived from mutant/wild-type TP53 may represent a therapeutic target. Interestingly, a p53 reactivator (PRIMA-1MET) showed promise in clinical trials of haematological malignancies; therefore, it warrants an in vitro evaluation in PC cell lines. To evaluate the antiproliferative effects of PRIMA-1MET, either alone or combined with the common chemotherapy 5-fluorouracil (5-FU), against mutated and wild-type p53 PC cell lines. This study involved p53-mutant (AsPC-1) and p53-wild type (Capan-2) PC cell lines. The cytotoxicity of PRIMA-1MET alone or in combination with 5-FU was evaluated by MTT assay. Synergism was assessed by calculating the combination index (CI) via CalcuSyn software. Fluorescence microscopy was used to analyse apoptosis following acridine orange/ethidium bromide (AO/EB) staining. Morphological changes were investigated with an inverted microscope. Quantitative reverse transcription PCR (RT‒qPCR) was used to measure gene expression. Both PC cell lines were sensitive to PRIMA-1MET monotherapy. Furthermore, PRIMA-1MET and 5-FU had a synergistic effect (CI < 1), reflected by significant enhancement of apoptosis and morphological changes in the combination vs. monotherapy treatments. Moreover, the RT‒qPCR results indicated increased expression of the NOXA and TP73 genes in combination-treated cells. Our data suggested that PRIMA-1MET, whether alone or combined with 5-FU, has an antiproliferative effect on PC cell lines regardless of p53 mutational status. The synergism of the combination was associated with significant apoptosis induction through p53-dependent and p53-independent pathways. Preclinical confirmation of these data in in vivo models is highly recommended.
Keywords: 5-FU; APR-246; Combination; P53 reactivator; PRIMA-1MET; Pancreatic cancer.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- Voutsadakis IA (2021) Mutations of p53 associated with pancreatic cancer and therapeutic implications. Annals of hepato-biliary-pancreatic surgery. 25(3):315–327. https://doi.org/10.14701/ahbps.2021.25.3.315
-
- Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP (2016) Pancreatic cancer. Nat Reviews Disease Primers 2(1):16022. https://doi.org/10.1038/nrdp.2016.22 - DOI - PubMed
-
- Muniraj T, Jamidar PA, Aslanian HR (2013) Pancreatic cancer: a comprehensive review and update. Dis Mon 59(11):368–402. https://doi.org/10.1016/j.disamonth.2013.08.001 - DOI - PubMed
-
- Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA: a cancer journal for clinicians. 63(1):11–30. https://doi.org/10.3322/caac.21166
-
- Simeone DM (2008) Pancreatic Cancer stem cells: implications for the treatment of pancreatic Cancer. Clin Cancer Res 14(18):5646–5648. https://doi.org/10.1158/1078-0432.ccr-08-0584 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
